ralaniten acetate developmental code name firstinclass antiandrogen targets nterminal domain ntd androgen receptor ar developed essa pharmaceuticals investigation treatment prostate mechanism action believed allow drug block signaling ar splice derivative bisphenol prodrug ralaniten one four stereoisomers developed successor drug reached phase iii prior discontinuation showed signs efficacy form prostatic specific antigen psa decreases predominantly higher doses mg patients also caused side effects discontinued developer favor nextgeneration ar ntd inhibitors improved potency antineoplastic immunomodulatory drug article stub help wikipedia expanding drug article relating genitourinary system stub help wikipedia expanding httpsenwikipediaorgwikiralanitenacetate